Online inquiry

IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4484MR)

This product GTTS-WQ4484MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD28 gene. The antibody can be applied in Lupus nephritis, Inflammatory diseases research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001243077.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 940
UniProt ID P10747
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ4484MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14600MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ54MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ12345MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ3228MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARGX-113
GTTS-WQ12091MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ6972MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ETI-204
GTTS-WQ2175MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ11267MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI4893
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW